Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe

Biochemical and Biophysical Research Communications

Volumn 363, Issue 4, 2007, Pages 1044-1049

  Park, Seok Soon ^a   Kim, Mi Ae ^a   Eom, Young Woo ^a   Choi, Kyeong Sook ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Apoptosis; Bcl xL; Doxorubicin; Hepatocellular carcinoma; Mitotic catastrophe

Indexed keywords

DOXORUBICIN; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOCHROMES C; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; MITOCHONDRIA; MITOSIS;

EID: 35148867159     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.037     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Hung H. Treatment modalities for hepatocellular carcinoma. Curr. Cancer Drug Targets 5 (2005) 131-138
3. Schwartz J.D., and Beutler A.S. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced heaptocellular carcinoma. Anticancer Drugs 15 (2004) 439-452
4. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
5. Bristow M.R., Billingham M.E., Mason J.W., and Daniels J.R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. 62 (1978) 873-879
6. Von Hoff D.D., Layard M.W., Basa P., Davis Jr. H.L., Von Hoff A.L., Rozencweig M., and Muqqia F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91 (1979) 710-717
7. Eom Y.W., Kim M.A., Park S.S., Goo M.J., Kwon H.J., Sohn S., Kim W.H., Yoon G., and Choi K.S. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24 (2005) 4765-4777
8. Roninson I.B., Broude E.V., and Chang B.D. If not apoptosis then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 4 (2001) 303-313
9. Mansilla S., Bataller M., and Portugal J. Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med. Chem. 6 (2006) 589-602
10. Park S.S., Eom Y.W., and Choi K.S. Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis. Biochem. Biophys. Res. Commun. 334 (2005) 1014-1021
11. Nitta M., Kobayashi O., Honda S., Hirota T., Kuninaka S., Marumoto T., Ushio Y., and Saya H. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 23 (2004) 6548-6558
12. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
13. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?. Genes Cells 3 (1998) 697-707
14. Takehara T., Liu X., Fujimoto J., Friedman S.L., and Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34 (2001) 55-61
15. Watanabe J., Kushihata F., Honda K., Suqita A., Tateishi N., Mominoki K., Matsuda S., and Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135 (2004) 604-612
16. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19 (2000) 6627-6631
17. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem. Biophys. Res. Commun. 333 (2005) 336-343
18. Tsujimoto Y., Shimizu S., Equchi Y., Kamiike W., and Matsuda H. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia Suppl. 3 (1997) 380-382
19. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., and Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6 (2004) 1221-1228
20. Dimanche-Boitrel M.T., Meurette O., Rebillard A., and Lacour S. Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist. Updat. 8 (2005) 5-14
21. Viktorsson K., Lewensohn R., and Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv. Cancer Res. 94 (2005) 143-196
22. Kim R., Emi M., and Tanabe K. The role of apoptosis in cancer cell survival and therapeutic overcome. Cancer Biol. Ther. 5 (2006) 1429-1442
23. Speth P.A., Linssen P.C., Boezeman J.B., Wessels H.M., and Haanen C. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother. Pharmacol. 20 (1987) 305-310
24. Scaffidi C., Schmitz I., Zha J., Korsemeyer S.J., Krammer P.H., and Peter M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 32 (1999) 22532-22538
25. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
26. Zou H., Li Y., Liu X., and Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274 (1999) 11549-11556
27. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487